Strategic Plan Objective Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Question 4: Objective 5  

$15,879,826.98
Fiscal Year: 2008

Green dot: Objective has greater than or equal to the recommended funding.4.5 Standardize and validate at least 20 model systems (e.g. cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012. IACC Recommended Budget: $75,000,000 over 5 years.

Download 2008 Question 4: Objective 5 projects (EXCEL)
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Institution
Aberrant synaptic function due to TSC mutation in autism Sulzer, David Columbia University Medical Center
A better understanding of the therapeutic actions of specific neuroleptics in autism Greengard, Paul The Rockefeller University
A mouse knock-in model for Engrailed 2 autism susceptibility Millonig, James University of Medicine & Dentistry of New Jersey - Robert Wood Johnson Medical School
Analysis of 15q11-13 GABA-A receptor defects in autism Hogart, Amber University of California, Davis
Analysis of FGF17 roles and regulation in mammalian forebrain development Hoch, Renee University of California, San Francisco
Animal models of neuropsychiatric disorders Crawley, Jacqueline National Institutes of Health
A non-human primate autism model based on maternal infection Patterson, Paul California Institute of Technology
Cellular and molecular alterations in gabaergic inhibitory circuits by mutations in MECP2, a gene implicated in the Rett syndrome of the autism spectrum disorders Huang, Z. Josh Cold Spring Harbor Laboratory
Cognitive mechanisms of serially organized behavior Terrace, Herbert Columbia University
Connectopathic analysis of autism Sanes, Joshua Harvard University
Distinct function of the neuroligin 3 postsynaptic adhesion complex Budreck, Elaine Columbia University
Dysregulation of p13/AKT in mouse models for social interaction deficits and for ASD with macrocephaly Parada, Luis University of Texas Southwestern Medical Center
Exploring the role of synaptic proteins in mouse models of autism Heintz, Nathaniel The Rockefeller University
Function and dysfunction of neuroligins Sudhof, Thomas Stanford University
Generation of genetic models of autism in mice Fishell, Gordon New York University School of Medicine
Genetic analyses of ARX homeobox gene function in neurodevelopmental disorders Sengupta, Piali Brandeis University
Genomic imbalances at the 22q11 locus and predisposition to autism Gogos, Joseph Columbia University
Investigation of the role of MET kinase in autism Dawson, Ted Johns Hopkins University School of Medicine
Mice lacking Shank postsynaptic scaffolds as an animal model of autism Sheng, Morgan Massachusetts Institute of Technology
Models and mechanisms - 1 Sur, Mriganka Massachusetts Institute of Technology
Models and mechanisms - 2 Sahin, Mustafa Boston Children's Hospital
Molecular determinants of L-type calcium channel gating Colecraft, Henry Columbia University
Neocortical regionalization: Analysis of genetic and epigenetic influences Huffman, Kelly University of California, Riverside
Neural and cognitive mechanisms of autism Sur, Mriganka Massachusetts Institute of Technology
Neurexin-neuroligin trans-syanptic interaction in learning and memory Kandel, Eric Columbia University

Objective Cumulative Funding Table

IACC Strategic Plan Objectives 2008 2009 2010 2011 2012 Total
Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012.

IACC Recommended Budget: $75,000,000 over 5 years
4.5
$15,879,827
42 projects

4.S.B
$20,162,709
70 projects

4.S.B
$23,229,501
92 projects

4.S.B
$21,606,118
89 projects

4.S.B
$21,232,514
94 projects

$102,110,669
4.S.B. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.

Progress: More than 90 projects were supported to develop animal models.

Remaining Gaps, Needs, and Opportunities: Planning Group members discussed whether the amount of investment in this area is appropriate when compared to investments in clinical trials and other later stage studies. Invited experts suggested that the current stage of scientific research in ASD requires pre-clinical research to identify targets from animal and cellular models. Similar to cancer treatment development pathways, which spanned 20-30 years, research in ASD must invest in model systems to understand the fundamental biology from which translation to the clinic can be built.  The translational validity of research in non-human animals cannot be determined until human trials are conducted, thus the need for rapid progress to clinical studies in humans is important.